Prostock Analysis

Treatment with ILUMYA should not be initiated in patients with a clinically important active infection until the infection resolves or is adequately treated. Consider the risks and benefits of treatment prior to prescribing ILUMYA in patients with a chronic infection or a history of recurrent infection. Evaluate patients for TB infection prior to initiating treatment with ILUMYA. Consider anti-TB therapy prior to initiation of ILUMYA in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed.

The Indian Energy Exchange (IEX), India’s largest Energy Exchange today assured distribution utilities and the nation of uninterrupted 24*7 access to its platform to support the utilities supply uninterrupted power during the ongoing COVID-19 crisis. The utilities are urged to leverage current low costs to ensure that critical sectors like healthcare, public utilities, businesses can ensure business continuity in the wake of COVID-19 and provide 24X7 power supply so that end-consumers do not struggle with power-cuts at this critical time. In today’s crisis situation, we are faced with the onerous responsibility to support and enable our customers in their endeavor to provide uninterrupted power supply to the currently stressed healthcare ecosystem in addition to all public utilities and related businesses that support it. We recognize Power as the lifeline of our country - at a time like this more than ever before - and will continue to ensure operational excellence, transparent price discovery and 24X7 support for all members and clients.

Ajanta Pharma Ltd. continues to strive hard to maintain un-interrupted supply of life-saving drugs in India and across the world with the help of Ajantaites, who are committed to play their role during this global crisis. Talking about the contribution Mr. Yogesh Agrawal, Managing Director, Ajanta Pharma said: “Ajanta’s mission to serve global healthcare needs through empathy, innovation and technology has come to the fore with the Company standing with the government and patients to overcome the humanitarian crisis triggered by the global spread of COVID-19. We salute the doctors, medical staffs and government authorities working selflessly for the cause and promise to tirelessly work towards ensuring availability of essential medicines. DURING INDIA’S HOUR OF NEED Cipla announces successful completion of Phase-3 clinical study for generic version of GSK’s Advair Diskus® Hester Biosciences Ltd Setting up of Manufacturing Science & Technology Division (MSAT) and appointment of Vice

In this situation, Government of India has set up a special fund -- PM CARES Fund - to secure donations for its fight against Covid-19 as the global pandemic poses a “never-before challenge” for which massive funds are needed. The Government has urged all the citizens including corporates to contribute generously in this fund to support the government in fighting against COVID-19. MOIL has already taken up various preventive measures at all its offices, mines, plant and residential townships to protect the employees and their families against the spread of CORONA virus. DURING INDIA’S HOUR OF NEED Cipla announces successful completion of Phase-3 clinical study for generic version of GSK’s Advair Diskus® Hester Biosciences Ltd Setting up of Manufacturing Science & Technology Division (MSAT) and appointment of Vice